BACKGROUND: In a 6-year, multicenter, prospective nested case-control study, we aimed to evaluate risk factors for incident cancer in inflammatory bowel disease (IBD), when considering clinical characteristics of IBD and immunomodulator use. The secondary end point was to provide characterization of incident cancer types. METHODS: All incident cases of cancer occurring in IBD patients from December 2011-2017 were prospectively recorded in 16 Italian Group for the Study of Inflammatory Bowel Disease units. Each of the IBD patients with a new diagnosis of cancer was matched with 2 IBD patients without cancer, according to IBD phenotype (ulcerative colitis [UC] vs Crohn's disease [CD]), age (\ub15 years), sex. Risk factors were assessed by mul...
Background & Aims: The combined role of immunomodulators (IMM) and clinical characteristics of I...
Background & Aims: The combined role of immunomodulators (IMM) and clinical characteristics of I...
Cancer risk in inflammatory bowel disease [IBD] is still debated. In a prospective, multicentre, nes...
BACKGROUND AND AIMS: Cancer risk in inflammatory bowel disease [IBD] is still debated. In a prospec...
BACKGROUND AND AIMS: Cancer risk in inflammatory bowel disease [IBD] is still debated. In a prospect...
In a 6-year, multicenter, prospective nested case-control study, we aimed to evaluate risk factors f...
In a 6-year, multicenter, prospective nested case-control study, we aimed to evaluate risk factors f...
OBJECTIVES: Population-based studies of site-specific cancer risk in patients with inflammatory bowe...
Cancer risk in inflammatory bowel disease [IBD] is still debated. In a prospective, multicentre, nes...
Cancer risk in inflammatory bowel disease [IBD] is still debated. In a prospective, multicentre, nes...
Cancer risk in inflammatory bowel disease [IBD] is still debated. In a prospective, multicentre, nes...
Cancer risk in inflammatory bowel disease [IBD] is still debated. In a prospective, multicentre, nes...
Cancer risk in inflammatory bowel disease [IBD] is still debated. In a prospective, multicentre, nes...
Cancer risk in inflammatory bowel disease [IBD] is still debated. In a prospective, multicentre, nes...
Cancer risk in inflammatory bowel disease [IBD] is still debated. In a prospective, multicentre, nes...
Background & Aims: The combined role of immunomodulators (IMM) and clinical characteristics of I...
Background & Aims: The combined role of immunomodulators (IMM) and clinical characteristics of I...
Cancer risk in inflammatory bowel disease [IBD] is still debated. In a prospective, multicentre, nes...
BACKGROUND AND AIMS: Cancer risk in inflammatory bowel disease [IBD] is still debated. In a prospec...
BACKGROUND AND AIMS: Cancer risk in inflammatory bowel disease [IBD] is still debated. In a prospect...
In a 6-year, multicenter, prospective nested case-control study, we aimed to evaluate risk factors f...
In a 6-year, multicenter, prospective nested case-control study, we aimed to evaluate risk factors f...
OBJECTIVES: Population-based studies of site-specific cancer risk in patients with inflammatory bowe...
Cancer risk in inflammatory bowel disease [IBD] is still debated. In a prospective, multicentre, nes...
Cancer risk in inflammatory bowel disease [IBD] is still debated. In a prospective, multicentre, nes...
Cancer risk in inflammatory bowel disease [IBD] is still debated. In a prospective, multicentre, nes...
Cancer risk in inflammatory bowel disease [IBD] is still debated. In a prospective, multicentre, nes...
Cancer risk in inflammatory bowel disease [IBD] is still debated. In a prospective, multicentre, nes...
Cancer risk in inflammatory bowel disease [IBD] is still debated. In a prospective, multicentre, nes...
Cancer risk in inflammatory bowel disease [IBD] is still debated. In a prospective, multicentre, nes...
Background & Aims: The combined role of immunomodulators (IMM) and clinical characteristics of I...
Background & Aims: The combined role of immunomodulators (IMM) and clinical characteristics of I...
Cancer risk in inflammatory bowel disease [IBD] is still debated. In a prospective, multicentre, nes...